Leu-Enkephalin

Leucine enkephalin (Leu-enkephalin; Tyr-Gly-Gly-Phe-Leu) is an endogenous opioid pentapeptide derived from proenkephalin A, co-discovered by John Hughes and Hans Kosterlitz in 1975 alongside methionine enkephalin as the first endogenous ligands identified for opiate receptors in the mammalian brain. Leu-enkephalin binds preferentially to delta opioid receptors and to a lesser extent mu receptors, producing analgesic effects and modulating pain signal transmission at spinal and supraspinal levels including the periaqueductal gray; rodent pharmacology studies have established its antinociceptive role in descending pain modulation pathways alongside other endogenous opioids. Exogenous administration of leu-enkephalin faces fundamental pharmacological barriers including a very short plasma half-life (seconds to minutes), near-complete first-pass metabolism by peptidases, and poor blood-brain barrier penetration, which have prevented its clinical development as an analgesic and explain the absence of human therapeutic trials. Leu-enkephalin is an endogenous opioid peptide with no FDA approval or therapeutic indication in any jurisdiction; it is a research tool compound used in receptor pharmacology and pain biology studies, and any provider listing should be understood as an educational reference rather than as a claim of established therapeutic utility.